Entering text into the input field will update the search result below

Health Canada approves Ipsen’s Sohonos for fibrodysplasia ossificans progressiva

Jan. 24, 2022 1:53 AM ETIpsen S.A. (IPSEY) StockIPSEFBy: SA News Team

Doctor on Canada flag background. 3d illustration

Rawf8/iStock via Getty Images

  • Ipsen (OTCPK:IPSEY) announces the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) in adults and children aged 8 years and above for females

Recommended For You

More Trending News

About IPSEY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
IPSEY--
Ipsen S.A.